Influenza
1,367
54
86
1,103
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
459 trials with published results (34%)
Research Maturity
1103 completed trials (81% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
3.1%
43 terminated out of 1367 trials
96.2%
+9.7% vs benchmark
36%
494 trials in Phase 3/4
42%
459 of 1103 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1103 completed trials
Clinical Trials (1367)
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
H5N1 Milk Detection Study
The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated Vaccine
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
BPL-1357 Against H1N1 Influenza Virus Challenge
Respiratory Virus Sampling and Repository
Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
pH1N1 Blinded Challenge Study
Noseguard for Prevention of Respiratory Infections in Real-World Use
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
Communication Intervention to Improve Influenza Vaccination Rates Among Elderly in Can Tho
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
Post-exposure Influenza Prophylaxis in a Hospital Setting
Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
Revealing Protective Immunity to Influenza Using Systems Immunology
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza